Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer
Wells S. Brown, Paul C. McDonald, Oksana Nemirovsky, Shannon Awrey, Shawn C. Chafe, David F. Schaeffer, Jinyang Li, Daniel J. Renouf, Ben Z. Stanger, Shoukat Dedhar
Abstract
and increased survival. We have identified an effective combinatorial treatment strategy using clinically viable inhibitors, which can be applied to PDAC tumors with different KRAS mutations.
Topics & Concepts
KRASmTORC1Cancer researchPancreatic cancerMAPK/ERK pathwayPI3K/AKT/mTOR pathwaySelumetinibProtein kinase BMEK inhibitormTORC2KinaseCancerChemistryBiologyPhosphorylationSignal transductionMedicineColorectal cancerInternal medicineCell biologyPI3K/AKT/mTOR signaling in cancerMultiple Myeloma Research and TreatmentsEnzyme function and inhibition